Equity Research, Broker Reports, and media content on ASTRAZENECA PLC

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about ASTRAZENECA PLC
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on ASTRAZENECA PLC. We currently have 14 research reports from 3 professional analysts.

Date Source Announcement
09Dec16 03:05 RNS FDA accepts durvalumab for BLA in bladder cancer
06Dec16 09:30 RNS Tagrisso data shows superiority over chemotherapy
05Dec16 07:00 RNS AZ completes agreement for Rhinocort Aqua rights
01Dec16 04:00 RNS Block listing Interim Review
01Dec16 03:00 RNS Total Voting Rights
22Nov16 07:00 RNS AZ head and neck cancer trials resume enrolment
17Nov16 07:00 RNS AZ out-licensing deal with Allergan completed
  • Frequency of research reports


  • Research reports on


  • Providers covering


Latest Content

View the latest research, videos, and podcasts for this company.

Breakfast Today

  • 11 Nov 16

"Just when investors though they would be waking up to the mother of all Trump hangovers, the Dow Jones surges to a fresh all-time record. But what's going on in the debt markets? After all, recent successful presidencies can be traced back to stability in US government bonds. Yesterday, the fixed income sell-off that started with Treasuries on Wednesday began to spread across the world as traders reacted to the prospect of a giant US fiscal stimulus, and have even started to ask whether Trump's victory in fact spells the end of their market's extended bull run. For sure, his proposal to hit US corporates with large offshore cash deposits with a one-time 10% charges, irrespective of whether the funds are repatriated or not, would go some way filling the IRS's coffers, even if there can be no certainty whether they would then choose to invest the surplus or simply give it back to shareholders. Indeed, this point was seen to unsettle tech stocks last night, with the NASDAQ quite sharply down while the Dow and S&P-500 remained well supported. Whatever, an unsettled and divided US yearns for clear vision and immediate action on where the economy is going and Trump knows that his credibility will be tested during his first 100 days in office. But even with control of both congressional chambers his far-reaching plans, ranging from tax reform to renegotiating global trade pacts, will still take as much as two years to become law. European leaders appear anxious to use this breathing space in order to consider their own position within a changing world order, as German Finance Minister, Wolfgang Schaeuble made clear in a speech yesterday. Meanwhile, with the Fed's Jeffrey Lacker overnight noted that the case for raising interest rates remains strong, Janet Yellen's scheduled testimony on Capitol Hill will undoubtedly be one of next week's highlights. Asia also put in a more sombre performance earlier today, as counterarguments circulated between brokers regarding the prospect of high import tariffs/international trade war and a reflated global economy, with the US$-biased Hang Seng being the only loser amongst other modestly firmer indices. With just UK construction figures due for release this morning and no major corporates due to report, London's markets are expected to largely tread water today awaiting more news from Washington; the FTSE-100 is seen fluctuating some 5 or so points either side of unchanged in early trading." - Barry Gibb, Research Analyst

Breakfast Today

  • 04 Oct 16

"Chancellor Philip Hammond’s speech at the party conference yesterday delivered on most expectations. As predicted, Sterling continued to be the fall guy, sliding close to a 30-year low against the US$, the results of which had already been amply demonstrated by the release of much stronger than expected September PMI data. Jettisoning his predecessor’s plan to achieve fiscal surplus by 2020, the market is now starting to call for much more that the relatively modest boosts provided to housebuilders/constructors and tech innovation in his speech. Indeed, since most forecasters expect next year’s enactment of Article 50 to compound investment uncertainty, resulting in slower growth and lower tax revenues, he will have to do more that just take his foot off the ‘austerity pedal’. Indeed, the government may see the need to fund significant new infrastructural and regeneration programmes, with a view to staunching a potential downward spiral in economic confidence or rocketing unemployment over the next 30 or so months. Not that Hammond wanted it, but the Fed’s William Dudley also reminded markets yesterday of the problems that continue to be experienced by the world’s increasingly impotent central banks. His statement noted insights being gathered “..have important implications for the appropriate path for monetary policy and the question of whether monetary policy makers need additional tools or greater support from the fiscal authorities”. Dudley’s suggestion was not particularly new, but still enough to send a shiver down the spine of the US equity markets, with all principal indices closing modestly negative as some cashed-in profits from the rally of the past few days. Asia closed mixed with only Japan making a reasonable gain due to a weaker Yen and despite the BoJ being forced to lower its inflation outlook still further. The Shanghai Composite was closed for the second day, leaving the Hang Seng and the ASX to make only fractional negative movements. The UK has no major macro data scheduled for release this morning, although the IMF will produce its World Economic Outlook. Amongst London’s corporates, earnings figures or trading updates are anticipated only from various second tier companies such as Greggs (GRG.L), Quantum Pharma (QP..L), Revolution Bars (RBG.L), ScS Group (SCS.L) and St Ives (SIV.L). Later this afternoon, Google is holding a media event in San Francisco, while traders will also be listening for further updates from RBS regarding its reported US$120m settlement with the US courts due to the lender’s underwriting of residential mortgage-backed securities before the 2008 financial crisis. London equities are seen opening in an undecided mood, with the FTSE-100 losing 5 or so points in early trading on relatively light volumes." - Barry Gibb, Research Analyst

A quarter of Brilinta, Farxiga and oncology

  • 30 Aug 16

AstraZeneca’s Q2 results lacked lustre, coming largely in line with our expectations, with the outperformance of product sales of $5.5bn being truncated by lower externalisation revenue, netting sales of $5.6bn. This represented a decline of 10% yoy (NB all revenue growth numbers at constant currency unless specified otherwise), emanating primarily from the Crestor (-29%) and Nexium (-13%) side of the business in the US. Currency had an adverse impact of 100bp. Cost containment, however, was better than our expectation, resulting in a lower decline in operating profit (adjusted for restructuring expense) to $611m, than anticipated. While the cost of sales marginally increased (+3.4%), due to the write-down of the FluMist inventory in the US and the adverse impact of the sales mix, SG&A (-0.7%) and R&D (-0.6%) remained flat reflecting efficiency gains in sales & marketing and IT costs. The core operating profit (which excludes restructuring, amortisation/depreciation/impairment, legal costs, etc.) was down by 21% to $1.4bn, while the reported operating profit plummeted 67.2% yoy to $303m. The debt pertaining to ZS Pharma and Acerta Pharma, further weighed on earnings, resulting in a net loss of $31m vs a profit of $696m in Q2 FY15. The CER guidance of a low to mid single-digit decline in both revenue and core EPS for the year has been maintained, although the FlumMist write-down will take the EPS number to the lower end of the range. Forex is now likely to have a positive impact of a low to mid single-digit on sales (vs earlier guidance of a negative 2% impact).

Breakfast Today

  • 25 Aug 16

"Traders are now unlikely to take any large market bets until the Federal Reserve Bank of Kansas City's two-day Monetary Policy Symposium at Jackson Hole, Wyoming has concluded. Top of the bill of course is Chair, Janet Yellen, who is formally scheduled to speak at 09:00hrs local time on Friday, but given the hype that has surrounded this event anything she finally divulges is likely to be considered something of an anti-climax as far as investors are concerned. Indeed, most probably she will continue to walk a fine line, offering positive but uncommitted descriptions of the current state of the US economy while keeping options open regarding a rate hike at the central bank's September meeting. That would leave the markets to tread water for a little longer yet. Overnight the US markets closed modestly weaker across all principal indices, giving back more than the previous day's gains, as concerns circulated in the media about possible political actions to tame escalating drug prices following the sharp increase imposed by Mylan Inc. on Epistem, its sever allergies treatment; crude oil also weakened again on further reflection of yesterday's surprisingly big build-up of US stockpiles, which was also seen to pressurise other recently well supported commodity prices. A lack of new stories in Asia left the regions equity markets to simply track the US, with the Shanghai Composite ending the session's the main casualty as the PBOC was seen injecting additional funds to stimulate otherwise lacklustre investor enthusiasm. Other than today's start of the Jackson Hole Symposium, macro releases due includes the CBI Distributive Trades Survey and the CML mortgage lending figures, while UK corporates due to publish earning numbers are Anglo Pacific Group (APF.L), CRH (CRH.L), Henry Boot (BHY.L), Jimmy Choo (CHOO.L), John Laing (JLG.L) and Spire Healthcare (SPI.L). The FTSE-100 is seen opening around 12 points lower in early, relatively low volume, trade." - Barry Gibb, Research Analyst

Breakfast Today

  • 10 Aug 16

"There was nothing particularly significant from the overnight markets to set the opening trend for London this morning, so investors are instead likely to focus back on yesterday’s report from the National Institute for Economic and Social Research, which reported that the UK economy shrunk by 0.2% in the first full month following Brexit, as political tensions and concerns regarding the UK’s prospective relationship with the EU knocked confidence. This, added to the Bank of England’s reported failure to buy back as many government bonds as it had targeted during the first couple of days of its six-month, £60bn programme, highlights the fact that the process of stimulating risk markets can never be straight forward. London equities accordingly look to be setback at the opening this morning, with the FTSE- 100 seen falling up to 15 points in early trade. Overnight, the US markets saw quiet, low volume activity push all three principal indices modestly into the positive, with the tech-heavy NASDAQ leading the way and closing at a new record high. Yen strength was again the main talking point in Asia as Japan reported June core machinery orders rebounding from previous weakness; while gains of half a percent against the US$ kept the Nikkei under pressure other markets in the region ended mixed with commodity stocks amongst the main losers. This morning the UK will report CML Housing Market Data while the BoE Agents’ Summary of Business Conditions is also due for release. Half-yearly earnings are also due from Centamin (CEY.L), G4S (GFS.L), Interserve (IRV.L), Trafalgar New Homes (TRAF.L) and the Prudential (PRU.L)." - Barry Gibb, Research Analyst